Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00183872 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT00183872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00183872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Completed
Start date
April 14, 2005
Completion date
October 20, 2015
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal neoplasms, gastric cancer